Your browser is no longer supported. Please, upgrade your browser.
Kiniksa Pharmaceuticals, Ltd.
Index- P/E- EPS (ttm)-2.82 Insider Own1.00% Shs Outstand68.11M Perf Week-11.12%
Market Cap998.94M Forward P/E- EPS next Y-2.33 Insider Trans-7.91% Shs Float29.47M Perf Month-19.31%
Income-184.40M PEG- EPS next Q-0.79 Inst Own94.20% Short Float14.35% Perf Quarter-31.67%
Sales- P/S- EPS this Y12.90% Inst Trans0.20% Short Ratio7.65 Perf Half Y-9.75%
Book/sh4.58 P/B3.19 EPS next Y20.10% ROA-45.30% Target Price- Perf Year-28.25%
Cash/sh4.74 P/C3.09 EPS next 5Y- ROE-49.50% 52W Range14.35 - 28.67 Perf YTD-17.20%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-48.97% Beta-
Dividend %- Quick Ratio10.50 Sales past 5Y- Gross Margin- 52W Low1.95% ATR0.96
Employees168 Current Ratio10.50 Sales Q/Q- Oper. Margin- RSI (14)31.56 Volatility5.73% 6.09%
OptionableYes Debt/Eq0.00 EPS Q/Q-36.00% Profit Margin- Rel Volume0.61 Prev Close14.62
ShortableYes LT Debt/Eq0.00 EarningsFeb 24 AMC Payout- Avg Volume553.00K Price14.63
Recom1.60 SMA20-9.94% SMA50-21.64% SMA200-20.27% Volume335,045 Change0.07%
Jun-29-20Reiterated BofA Securities Buy $25 → $40
Apr-01-20Initiated BofA/Merrill Buy $25
Mar-11-19Initiated Barclays Overweight $26
Dec-12-18Reiterated Wedbush Outperform $31 → $33
Jun-19-18Initiated JMP Securities Mkt Outperform $33
May-04-21 08:00AM  
Apr-12-21 07:30AM  
Apr-01-21 08:00AM  
Mar-19-21 10:55AM  
Mar-18-21 04:30PM  
Mar-04-21 08:12AM  
Mar-02-21 08:00AM  
Feb-28-21 10:54AM  
Feb-23-21 08:00AM  
Feb-17-21 04:15PM  
Jan-27-21 09:36AM  
Jan-11-21 08:00AM  
Jan-04-21 04:20PM  
Dec-22-20 08:00AM  
Dec-18-20 08:51AM  
Dec-15-20 08:00AM  
Nov-30-20 08:00AM  
Nov-24-20 08:00AM  
Nov-23-20 08:00AM  
Nov-17-20 08:00AM  
Nov-16-20 08:00AM  
Nov-10-20 09:15AM  
Nov-09-20 04:01PM  
Nov-05-20 07:30AM  
Oct-29-20 08:00AM  
Oct-26-20 08:00AM  
Oct-14-20 09:54PM  
Oct-07-20 10:14AM  
Oct-06-20 08:00AM  
Sep-24-20 04:12PM  
Sep-21-20 08:00AM  
Sep-15-20 08:00AM  
Sep-09-20 04:01PM  
Aug-31-20 08:00AM  
Aug-04-20 08:00AM  
Jul-30-20 07:30AM  
Jul-28-20 03:42PM  
Jul-21-20 09:55PM  
Jul-20-20 04:07PM  
Jul-16-20 07:30AM  
Jul-08-20 12:53PM  
Jul-05-20 11:03PM  
Jun-30-20 09:56AM  
Jun-29-20 03:47PM  
Jun-17-20 08:00AM  
Jun-12-20 10:43AM  
Jun-10-20 08:00AM  
Jun-08-20 08:00AM  
Jun-04-20 08:00AM  
May-29-20 08:30AM  
May-22-20 08:56AM  
May-18-20 04:01PM  
May-13-20 11:12PM  
May-11-20 07:30AM  
May-06-20 11:43AM  
Apr-28-20 07:30AM  
Apr-22-20 08:00AM  
Apr-08-20 11:30AM  
Apr-06-20 07:45PM  
Apr-01-20 09:04AM  
Mar-31-20 08:15AM  
Mar-30-20 07:30AM  
Feb-26-20 07:30AM  
Feb-11-20 09:12AM  
Feb-05-20 09:21AM  
Jan-13-20 08:00AM  
Dec-19-19 10:13AM  
Dec-18-19 02:27PM  
Dec-16-19 07:29AM  
Dec-12-19 09:59AM  
Dec-11-19 09:47AM  
Dec-10-19 08:00AM  
Dec-07-19 07:07AM  
Nov-21-19 10:22AM  
Nov-20-19 04:01PM  
Nov-16-19 12:00PM  
Nov-12-19 04:01PM  
Nov-01-19 10:55AM  
Oct-28-19 04:01PM  
Oct-08-19 04:48AM  
Sep-19-19 04:01PM  
Aug-19-19 07:30AM  
Aug-12-19 04:02PM  
Aug-06-19 07:30AM  
Aug-05-19 07:30AM  
Jun-29-19 06:17PM  
Jun-12-19 07:30AM  
Jun-10-19 11:26AM  
May-30-19 04:01PM  
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its product candidates include Rilonacept, which is in Phase III clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody that is in Phase II clinical trials for the treatment of giant cell arteritis; and Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition. The company's preclinical product candidates comprise KPL-404, a monoclonal antibody inhibitor of the CD40/CD40L interaction, a central control node of T-cell-dependent, and B-cell-mediated humoral adaptive immunity. The company has a clinical collaboration with Kite Pharma, Inc. to evaluate the combination of Yescarta and Mavrilimumab in patients with relapsed or refractory Large B-Cell lymphoma. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Patel Sanj KChairman & CEOFeb 10Option Exercise1.591,6002,5441,600Feb 10 07:07 PM
Patel Sanj KChairman & CEOFeb 10Sale23.071,13726,23183,336Feb 10 07:07 PM
Patel Sanj KChairman & CEOFeb 10Sale23.061,60036,8960Feb 10 07:07 PM
Patel Sanj KChairman & CEOFeb 09Option Exercise1.5920,40132,43820,401Feb 10 07:07 PM
Patel Sanj KChairman & CEOFeb 09Sale23.0823,569543,97384,473Feb 10 07:07 PM
Patel Sanj KChairman & CEOFeb 09Sale23.0420,401470,0390Feb 10 07:07 PM
Patel Sanj KChairman & CEOFeb 08Option Exercise1.594,9247,8294,924Feb 10 07:07 PM
Patel Sanj KChairman & CEOFeb 08Sale23.004,528104,144108,042Feb 10 07:07 PM
Patel Sanj KChairman & CEOFeb 08Sale23.004,924113,2520Feb 10 07:07 PM
Beetham Thomas W.EVP & Chief Legal OfficerFeb 03Sale22.092,47754,717297,523Feb 05 06:55 PM
Patel Sanj KChairman & CEOOct 12Option Exercise1.59150,700239,613150,700Oct 14 05:22 PM
Patel Sanj KChairman & CEOOct 12Sale21.0299,3302,087,917112,570Oct 14 05:22 PM
Patel Sanj KChairman & CEOOct 12Sale21.02150,7003,167,7140Oct 14 05:22 PM
Patel Sanj KChairman & CEOOct 09Option Exercise1.598721,386872Oct 14 05:22 PM
Patel Sanj KChairman & CEOOct 09Sale21.0067014,070211,900Oct 14 05:22 PM
Patel Sanj KChairman & CEOOct 09Sale21.0087218,3120Oct 14 05:22 PM
Beetham Thomas W.EVP & Chief Legal OfficerJul 01Sale25.3729,589750,6780Jul 02 04:13 PM
Beetham Thomas W.EVP & Chief Legal OfficerJun 10Option Exercise1.5913,75221,86643,341Jun 12 05:50 PM
Beetham Thomas W.EVP & Chief Legal OfficerJun 10Sale25.0713,752344,76329,589Jun 12 05:50 PM